No Data
No Data
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and Arcutis Biotherapeutics (ARQT)
Earnings Preview: BBIO to Report Financial Results Pre-market on February 20
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $49
BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025
BridgeBio Pharma Is Maintained at Sector Outperform by Scotiabank
BridgeBio Pharma Analyst Ratings